跳至主要内容
临床试验/NCT06658730
NCT06658730招募中不适用

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

W.L.Gore & Associates41 个研究点 分布在 10 个国家目标入组 1,500 人开始时间: 2025年6月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,500
试验地点
41
主要终点
Loss of aortic / branch patency

研究概览

简要总结

An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements.
  • •Patient has been or is intended to be treated with an eligible registry device.*
  • •Patient is age ≥ 18 years at time of informed consent signature.
  • •The intent to treat a patient with a Gore product must be made prior to soliciting for possible registry participation. If pre-procedure consent is not feasible due to emergent situation, consent prior to the time of discharge for the index procedure is acceptable.

排除标准

  • •Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.
  • •Patient with exclusion criteria required by local law.
  • •Patient is currently enrolled in or plans to enroll in any concurrent investigational drug and/or investigational device study* within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.
  • •The term "study" does not apply to other observational registries or quality improvement projects. Collection of Registry Device performance from interventional studies may be permissible provided device application is not investigational and there are no novel requirements that alter follow-up conduct (i.e., protocol-mandated interventions).

研究组 & 干预措施

Aneurysm/Other Isolated Lesion

干预措施: Endovascular (Device)

Dissection

干预措施: Endovascular (Device)

结局指标

主要结局

Loss of aortic / branch patency

时间窗: Through 10 years post-procedure

No flow or contrast detected through the implanted aortic and/or branch component (for branched devices) confirmed with imaging and/or direct observation.

Deployment Technical Success

时间窗: Index Procedure

* Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system. * The absence of any additional corrective procedure related to the device, procedure, or withdrawal of the delivery system. Events will not include interventions at the access site(s), lumbar drains to address spinal cord ischemia, or additional interventions to address non-treatment areas.

Lesion-related Mortality

时间窗: From time of index procedure through 10 years of follow-up

Death meeting at least one of the following characteristics: * Death within 30 days of the index procedure or following conversion to open repair. * Death within 30 days following a complication from a secondary procedure associated with the index lesion or registry device. * Any death where the treated disease / index lesion or registry device caused or significantly contributed to the death, including lesion-rupture, aortic-related complications, disease progression involving the index lesion.

Lesion Rupture (treated area)

时间窗: Through 10 years post-procedure

Rupture in the treated segment of the vessel (e.g., aorta or branch) verified with direct observation or CT / CTA scan.

Lesion Enlargement (treated area)

时间窗: Through 10 years post-procedure

An increase in maximum vessel (e.g., aorta or treated branch) diameter of \> 5 mm in the region encompassed by the initial lesion as compared to baseline using orthogonal (i.e., perpendicular to the centerline) measurements on CT / CTA scans.

Endoleaks

时间窗: Through 10 years post-procedure

Perfusion of a treated lesion via: * Type I endoleak is defined as a sealing failure at one of the attachment zones of the graft to the vessel wall, whereby arterial flow perfuses the treated lesion via a perigraft channel: * Type Ia: Proximal aortic attachment zone * Type Ib: Distal aortic attachment zone * Type Ic: Distal attachment zone for branch component * Type II: Retrograde flow from native aortic branch arteries * Type III endoleak: Component disconnection or fabric disruption resulting in arterial flow into the perigraft space * Type IIIa: Attachment of aortic components (aortic-aortic) * Type IIIb: Fabric tear or disruption * Type IIIc: Attachment of aortic component-side-branch or side-branch-side-branch * Type IV: Late endoleak due to flow through porous fabric * Type V/Endotension: Aneurysm sac enlargement \> 5 mm with no imaging evidence of an endoleak * Indeterminate: Endoleak is identified, but source cannot be ascertained

Device Migration

时间窗: Through 10 years post-procedure

Longitudinal movement of all or part of the device for a distance ≥ 10 mm, as confirmed by CTA scan, relative to anatomical landmarks and device positioning at the first post-operative CTA scan.

Stroke (All, Serious, Non-Serious)

时间窗: Through 10 years post-procedure

Stroke is the acute onset of symptoms consistent with focal or multifocal Central Nervous System (CNS) injury caused by vascular blockage resulting in ischemia or vascular rupture resulting in hemorrhage, that: * Persists for \> 24 hours or until death -or- * Symptoms lasting \< 24 hours, with pathology or neuroimaging confirmation of CNS infarction

Paraplegia (within 30 days of index procedure)

时间窗: Within 30 days of index procedure

New onset spinal cord injury rendering a subject non-ambulatory within 30 days of the index procedure

Paraparesis (within 30 days of index procedure)

时间窗: Within 30 days of index procedure

New onset spinal cord injury causing a minor motor deficit of the lower extremities within 30 days of the index procedure

New onset renal failure (within 30 days of index procedure)

时间窗: Within 30 days of index procedure

New onset sustained renal failure identified within 30 days of the index procedure, combined with requiring dialysis for \> 4 weeks

Renal function deterioration

时间窗: Within 30 days of index procedure

New onset of a decrease in eGFR \> 30% following treatment when compared to baseline eGFR.

Device integrity events (e.g., fracture, kinking, compression)

时间窗: Through 10 years post-procedure

Defined as any of the following: * Wire fractures, including stents, hooks, or barbs * Stent kinking: Narrowing of the stent graft associated with demonstrable angulation in any of the stent components, with demonstrable flow * Disruption/tears in the graft component of the stent graft Stent compression or invagination: Transient or permanent stent-graft collapse following complete device deployment, resulting in an overall reduction in the vessel luminal diameter

Reintervention

时间窗: Through 10 years post-procedure

Additional surgical or interventional procedure related to the treated disease / index lesion, the registry device, or to the treatment / procedure. This may include surgical or interventional treatment for endoleaks, access site(s) complications, disease progression (including interventions to address issues related to non-treated area of the index lesion, such as bare stent implantation to address bowel ischemia associated with aortic dissection), spinal drains for Spinal Cord Injury (SCI) management, or conversion to open surgery.

次要结局

  • Access-related complications(Intra-operatively)
  • Transient Ischemic Attack (TIA)(Through 10 years post-procedure)
  • New Dissection(Through 10 years post-procedure)
  • False Lumen Status - treated segment(Through 10 years post-procedure)
  • False Lumen Status - untreated segment(Through 10 years post-procedure)
  • False Lumen Perfusion(Through 10 years post-procedure)

研究者

发起方
W.L.Gore & Associates
申办方类型
Industry
责任方
Sponsor

研究点 (41)

Loading locations...

相似试验